What question did this study set out to answer?

To evaluate the congruence between prerequisite molecular biomarker testing and receipt of personalized therapies in non-small cell lung cancer, and to determine its impact on overall survival.

May 10, 2025International Journal of Molecular SciencesOpen Access

Incongruence Between Prerequisite Molecular Testing and Treatment with Personalized Therapies for Non-Small Cell Lung Cancer: A Surveillance, Epidemiology and End Results-Medicare Study

View Full Paper

Ask AI

Bookmark

To evaluate the congruence between prerequisite molecular biomarker testing and receipt of personalized therapies in non-small cell lung cancer, and to determine its impact on overall survival.
Retrospective cohort study analyzing Surveillance, Epidemiology, and End Results (SEER)-Medicare-linked data from older patients with non-small cell lung cancer (N = 911) treated with personalized therapy.
Compared baseline demographic and clinical features between tested and untested cohorts, evaluating overall survival via Kaplan-Meier curves and multivariable Cox proportional hazards regression adjusted for age, race, sex, socioeconomic status, histology, and stage.
Only 56.3% of treated patients (513 of 911) received prior molecular testing, with Black patients significantly less likely to undergo testing than White patients (36.4% vs. 59.9%, p < 0.001), and only 39.9% of EGFR inhibitor recipients tested for EGFR mutations.
Untested patients had significantly shorter median survival compared to tested patients (8.22 vs. 12.79 months, p = 0.024) and experienced higher mortality risk after multivariable adjustment (adjusted HR 1.20; 95% CI: 1.04–1.40).

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Cohort study reveals increased mortality from personalized therapies without prior molecular testing in lung cancer, highlighting the necessity of standardized diagnostic protocols.

Cite This Study

Turner et al. (2025) studied this question.

synapsesocial.com/papers/6a6f7942e5469ee92be0691d https://doi.org/10.3390/ijms26104581

View Full Paper

Ask AI

Bookmark

Implication

Cohort study reveals increased mortality from personalized therapies without prior molecular testing in lung cancer, highlighting the necessity of standardized diagnostic protocols.

Incongruence Between Prerequisite Molecular Testing and Treatment with Personalized Therapies for Non-Small Cell Lung Cancer: A Surveillance, Epidemiology and End Results-Medicare Study

Key Points

Discussion

Implication

Cite This Study

Incongruence Between Prerequisite Molecular Testing and Treatment with Personalized Therapies for Non-Small Cell Lung Cancer: A Surveillance, Epidemiology and End Results-Medicare Study

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider